Psychotropic alternatives to antipsychotic medications in treating dementia behaviors: An evidence-based practice protocol

Journal of Psychosocial Nursing and Mental Health Services

Volumn 54, Issue 10, 2016, Pages 46-53

  Birtley, Nancy M ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b Psych Care Consultants Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

DEMENTIA; EVIDENCE BASED PRACTICE; HUMAN; NURSING HOME;

ANTIPSYCHOTIC AGENTS; DEMENTIA; EVIDENCE-BASED PRACTICE; HUMANS; NURSING HOMES;

EID: 85029942115     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20160920-08     Document Type: Article

References (30)

1. Alzheimer’s Association. (2015). 2015 Alzheimer’s disease facts and figures. Retrieved from http://www.alz.org/facts/downloads/facts_figures_2015.pdf
2. Alzheimer’s Association. (n.d.). Stages/behaviors. Retrieved from https://www.alz.org/care/alzheimers-dementia-stages-behaviors.asp
3. Ballard, C.G., Waite, J., & Birks, J. (2012). Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews, 2012, 1-131. doi:10.1012/14651858.CD003476.pub2
4. Bonner, A. (2013). Improving dementia care and removing unnecessary use of antipsychotic medications in nursing homes. Retrieved from https://www.cms.gov/outreach-and-education/outreach/npc/downloads/2013-01-31-dementia-care-presentation.pdf
5. Buhr, G.T., Kuchibhatla, M., & Clipp, E.C. (2006). Caregiver’s reasons for nursing home placement: Clues for improving discussions with families prior to the transition. The Gerontologist, 46, 52-61. doi:10.1093/geront/46.1.52
6. Centers for Medicare & Medicaid Services. (2013). Advanced copy: Dementia care in nursing homes: Clarification to Appendix P State Operations Manual (SOM) and Appendix PP in the SOM for F309—Quality of Care and F329—Unnecessary drugs. Retrieved from https://www.cms.gov/medicare/provider-enrollment-and-certification/surveycertificationgeninfo/downloads/survey-and-cert-letter-13-35.pdf
7. Centers for Medicare & Medicaid Services. (2014). Data show National Partnership to Improve Dementia Care exceeds goals to reduce unnecessary antipsychotic medications in nursing homes. Retrieved from http://cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2014-Fact-sheets-items/2014-09-19.html
8. Centers for Medicare & Medicaid Services. (n.d.). Nursing home compare. Retrieved from http://www.medicare.gov/NursingHomeCompare/search.html
9. Cummings, J.L., Schneider, E., Tariot, P.N., & Graham, S.M. (2006). Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology, 67, 57-63. doi:10.1212/01.wnl.0000223333.42368.f1
10. Finkel, S.I., Mintzer, J.E., Dysken, M., Krishnan, K.R.R., Burt, T., & McRae, T. (2004). A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil. International Journal of Geriatric Psychiatry, 19, 9-18. doi:10.1002/gps.998
11. Fitzsimmons, S., Barba, B., Stump, M., & Bonner, A. (2014). Nonpharmacological interventions in long term care: Feasibility and recent trends. Journal of Gerontological Nursing, 40(5), 10-14. doi:10.3928/00989134-20140324-04
12. Herrmann, N., Lanctôt, K., Rothenburg, L.S., & Eryavec, G. (2007). A placebo-controlled trial of valproate for agitation and aggression in Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 23, 116-119. doi:10.1159/000097757
13. Herrmann, N., Lanctôt, K.L., Sambrook, R., Lesnikova, N., Hérbert, R., McCracken, P., Nguyen, E. (2006). The contribution of neuropsychiatric symptoms to the cost of dementia care. International Journal of Geriatric Psychiatry, 21, 972-976. doi:10.1002/gps.1594
14. Huybrechts, K.F., Gerhard, T., Crystal, S., Olfson, M., Avorn, J., Levin, R., Schneeweiss, S. (2012). Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: Population based cohort study. British Medical Journal, 344, 1-12. doi:10.1136/bmj.e977
15. Kales, H.C., Kim, H.M., Zivin, K., Valenstein, M., Seyfried, L.S., Chiang, C., Blow, F.C. (2012). Risk of mortality among individual antipsychotics in patients with dementia. American Journal of Psychiatry, 169, 71-79. doi:10.1176/appi.ajp.2011.11030347
16. Maher, A.R., Maglione, M., Bagley, M., Suttorp, M., Hu, J.H., Ewing, B., Shekelle, P.G. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. Journal of the American Medical Association, 306, 1359-1369. doi:10.1001/jama.2011.1360
17. Melnyk, B.M., & Fineout-Overholt, E. (Eds.) (2011). Making the case for evidence-based practice and cultivating a spirit of inquiry. In Evidence-based practice in nursing and healthcare: A guide to the best practice (2nd ed.). Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins.
18. Mohamed, S., Rosenheck, R., Lyketsos, C.G., Kaczynski, R., Sultzer, D., & Schneider, L.S. (2012). Effects of second-generation antipsychotics on caregiver burden in Alzheimer’s disease. Journal of Clinical Psychiatry, 73, 121-128. doi:10.4088/JCP.10m06574
19. Pariente, A., Fourrier-Réglat, A.F., Ducruet, T., Farrington, P., Béland, S.G., Dartigues, J.F., Moride, Y. (2012). Antipsychotic use and myocardial infarction in older patients with treated dementia. Archives of Internal Medicine, 172, 648-653. doi:10.1001/archinternmed.2012.28
20. Pollock, B.G., Mulsant, B.H., Rosen, J., Mazumdar, S., Blakesley, R.E., Houck, P.R., & Huber, K.A. (2007). A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psychiatry, 15, 942-952.
21. Porsteinsson, A.P., Tariot, P.N., Erb, R., Cox, C., Smith, E., Jakimovich, L., Irvine, C. (2001). Placebo-controlled study of divalproex sodium for agitation in dementia. American Journal of Geriatric Psychiatry, 9, 58-66.
22. Porsteinsson, A.P., Tariot, P.N., Jakimovich, L.J., Kowalski, N., Holt, C., Erb, R., & Cox, C. (2003). Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. American Journal of Geriatric Psychiatry, 11, 434-440. doi:10.1097/00019442-200307000-00006
23. Schneider, L.S., Dagerman, K.S., & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934-1943. doi:10.1001/jama.294.15.1934
24. Seitz, D.P., Adunuri, N., Gill, S.S., Grunier, A., Herrmann, N., & Rochon, P. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, 2, CD008191. doi:10.1002/14651858.CD008191.pub2
25. Selbaek, G., Engedal, K., & Bergh, S. (2013). The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: A systematic review. Journal of the American Medical Directors Association, 14, 161-169. doi:10.1016/j.jamda.2012.09.027
26. Siddique, H., Hynan, L.S., & Weiner, M.F. (2009). Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer’s disease. Journal of Clinical Psychiatry, 70, 915-918. doi:10.4088/JCP.08m04828
27. Sultzer, D.L., Davis, S.M., Tariot, P.N., Dagerman, K.S., Lebowitz, B.D., Lyketsos, C.G., Schneider, L.S. (2008). Clinical symptom response to atypical antipsychotic medications in Alzheimer’s disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry, 165, 844-854. doi:10.1176/appi.ajp.2008.07111779
28. Tariot, P.N., Farlow, M.R., Grossberg, G.T., Graham, S.M., McDonald, S., & Gergel, I. (2004). Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil. Journal of the American Medical Association, 291, 317-324. doi:10.1001/jama.291.3.317
29. Tariot, P.N., Raman, R., Jakimovich, L., Schneider, L., Porsteinsson, A., Thomas, R., Thal, L. (2005). Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation. American Journal of Geriatric Psychiatry, 13, 942-949.
30. U.S. Food and Drug Administration. (2010). Public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Retrieved from http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171